Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

World's largest family cord blood bank adopts GE healthcare system for processing cord blood

AZDEL : 25 August, 2007  (Technical Article)
GE Healthcare, a subsidiary of the General Electric Company and Cord Blood Registry announced today that CBR is automating the key production steps for their cord blood stem cell units using GE Healthcare's AutoXpress System.
AutoXpress is an automated, functionally-closed, sterile system that harvests mononuclear cell fraction from cord blood, capturing the stem cell rich portion of the blood into a final volume of product that is defined by the user. The AutoXpress technology platform products were developed by ThermoGenesis Corp. and are now distributed exclusively by GE Healthcare to customers all over the world.

'CBR is committed to providing our clients with the highest quality processing and storage of their child's new born stem cells, and we are continuously investigating new technologies to improve the effectiveness with which these precious stem cells are harvested from the collected umbilical cord blood,' said Tom Moore, CBR's Chief Executive Officer. 'After rigorous testing at our facility, we have determined that when combined with our proprietary collection technology, the AutoXpress System consistently recovers a median of 99% of the stem cell-rich mononuclear cell population from units of collected cord blood. This is a remarkable accomplishment and a significant improvement over the 75 - 90% recoveries practiced by many public and family cord blood banks and reported in peer-review journal reports.'

According to Ann O'Hara, general manager of Bioprocess at GE Healthcare, 'The AXP product platform was designed to improve the quality and consistency of cord blood stem cell units therefore improving the probability of good patient outcomes. We are very pleased that CBR, in particular, has chosen the AXP technology as it is strong affirmation of both the platform's capabilities and its use at very large scale.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo